• BeyondSpring set a management transition effective July 1, 2026, to focus on its confirmatory DUBLIN-4 Phase 3 program for Plinabulin in NSCLC.
• Founder Lan Huang will remain chairman, shifting day-to-day focus to SEED Therapeutics, where she is co-founder, chairman, CEO.
• Director Jiangwen (Jen) Majeti will become vice chairman; she has held senior roles at Amgen, Roche, BioDuro/PPD, Erasca.
• Min Qiu will take over as CEO; he has led corporate development work for five years, previously served as board secretary at Guangyuyuan.
• Na Li will become CFO; she has been CFO of Dalian Wanchunbulin Pharmaceutical since 2020, with two decades of finance leadership.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeyondSpring Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606040700PRIMZONEFULLFEED9731678) on June 04, 2026, and is solely responsible for the information contained therein.